Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases

A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period. The patients' age, date of first treatment, and th...

Full description

Saved in:
Bibliographic Details
Main Authors: John Buscombe, Daniel Gillett, Nick Bird, Anne Powell, Sarah Heard, Luigi Aloj
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2021-04-01
Series:World Journal of Nuclear Medicine
Subjects:
carcinoma of the prostate
median overall survival
radium-223
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_74_20
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items